Related Experiment Videos
WC3 reassortant vaccines in children
H F Clark1, P A Offit, R W Ellis
1Department of Pediatrics, University of Pennsylvania, Philadelphia, USA.
Archives of Virology. Supplementum
|January 1, 1996
Summary
Bovine rotavirus strain WC3 vaccine showed inconsistent protection against rotavirus disease in infants. However, a quadrivalent reassortant vaccine expressing human rotavirus surface proteins demonstrated significant protection against all rotavirus disease.
Area of Science:
- Virology
- Vaccinology
- Pediatrics
Background:
- Bovine rotavirus strain WC3 (P7[5], G6) was evaluated for infant tolerance and immunogenicity.
- Initial trials showed inconsistent protection against rotavirus disease, though some protection against severe cases was observed.
Purpose of the Study:
- To assess the efficacy of a quadrivalent bovine-P[5] human-G reassortant rotavirus vaccine in infants.
- To evaluate the vaccine's ability to induce protection against rotavirus gastroenteritis.
Main Methods:
- Development of WC3 reassortants expressing human rotavirus VP7 (G) or VP4 (P) surface antigens.
- A multicenter trial involving 439 infants to test a quadrivalent reassortant vaccine (G1, G2, G3, P1A[8]).
- Rotavirus disease diagnosis using ELISA for antigen and electropherotype analysis for RNA.
Main Results:
- The quadrivalent reassortant vaccine induced 67.1% protection against all rotavirus disease (ELISA positive).
- Protection increased to 72.6% when confirmed by ELISA and RNA electropherotype analysis.
- Severe rotavirus disease episodes (clinical severity score > 16.0) occurred exclusively in placebo recipients.
Conclusions:
- The quadrivalent reassortant rotavirus vaccine is effective in protecting infants against rotavirus disease.
- This vaccine strategy shows promise for preventing rotavirus gastroenteritis in pediatric populations.